HHS

CLIA looks to expand virtual access, update lab staffing rules, and modernize oversight as CMS and CDC review regulations.

AZ argues CMS exceeded authority under the Inflation Reduction Act by grouping separate medicines under a single drug definition.

New CMS rules require hospitals to disclose more accurate pricing data, aiming to improve price comparisons and patient decision-making.

Leading physician organizations push back after HHS Secretary said AI could outperform doctors and combat “medical tyranny.”

CMS finalized a mandatory Medicare Part B payment model using pricing benchmarks to test lower drug costs while maintaining care quality.

The program addresses longstanding challenges in clinical development, where bringing a new drug or biologic to market can take over a decade.

House Democrats propose reversing healthcare cuts, protecting vaccine access, lowering costs, and expanding coverage in the next Congress.

Debates over leadership at the CDC and FDA underscore growing concerns about scientific independence and public trust in health agencies.